# A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines

> **NCT05074459** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 84 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Eptinezumab Mammalian Cell Line
- **DRUG:** Eptinezumab Yeast Cell Line

## Key facts

- **NCT ID:** NCT05074459
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-27
- **Primary completion:** 2022-07-18
- **Final completion:** 2022-07-18
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2022-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05074459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05074459, "A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05074459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*